In Competitive RSV Market, GSK Aims To Be First For Adults 50-59

 
• By Jessica Merrill and Sarah Karlin-Smith
  
building blocks
GSK is hoping to build out the label for its RSV vaccine • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anti-infective

More from Therapeutic Category